A detailed history of Royal Bank Of Canada transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Royal Bank Of Canada holds 16,662 shares of AVXL stock, worth $94,640. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,662
Previous 16,733 0.42%
Holding current value
$94,640
Previous $85,000 17.65%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.39 - $5.02 $240 - $356
-71 Reduced 0.42%
16,662 $70,000
Q1 2024

May 15, 2024

SELL
$4.55 - $6.75 $91,359 - $135,533
-20,079 Reduced 54.54%
16,733 $85,000
Q4 2023

Feb 14, 2024

BUY
$5.04 - $9.95 $68,559 - $135,349
13,603 Added 58.61%
36,812 $342,000
Q3 2023

Nov 14, 2023

BUY
$6.55 - $9.37 $17,318 - $24,774
2,644 Added 12.86%
23,209 $152,000
Q2 2023

Aug 14, 2023

BUY
$7.66 - $9.5 $14,783 - $18,335
1,930 Added 10.36%
20,565 $167,000
Q1 2023

May 15, 2023

SELL
$8.32 - $11.75 $51,400 - $72,591
-6,178 Reduced 24.9%
18,635 $159,000
Q4 2022

Feb 14, 2023

BUY
$7.65 - $14.43 $79,560 - $150,072
10,400 Added 72.16%
24,813 $229,000
Q3 2022

Nov 14, 2022

BUY
$8.9 - $12.86 $4,076 - $5,889
458 Added 3.28%
14,413 $149,000
Q2 2022

Aug 15, 2022

SELL
$7.31 - $12.84 $26,893 - $47,238
-3,679 Reduced 20.86%
13,955 $140,000
Q1 2022

May 16, 2022

SELL
$9.74 - $17.69 $94,750 - $172,088
-9,728 Reduced 35.55%
17,634 $218,000
Q4 2021

Feb 14, 2022

BUY
$16.88 - $23.31 $190,153 - $262,587
11,265 Added 69.98%
27,362 $475,000
Q3 2021

Nov 15, 2021

BUY
$16.82 - $25.75 $60,703 - $92,931
3,609 Added 28.9%
16,097 $289,000
Q2 2021

Aug 16, 2021

BUY
$10.16 - $28.86 $126,878 - $360,403
12,488 New
12,488 $286,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $443M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.